<DOC>
	<DOCNO>NCT00002684</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , ifosfamide , paclitaxel , use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : This phase II trial study well combination chemotherapy work treat patient metastatic urinary tract cancer treat surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Patients With Advanced Urinary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy cisplatin , ifosfamide , paclitaxel patient unresectable metastatic urothelial cancer ( nontransitional cell histology ) . OUTLINE : Patients receive paclitaxel IV 3 hour cisplatin IV 1 hour day 1 ifosfamide IV 1 hour day 1-3 . Filgrastim ( G-CSF ) administer subcutaneously daily begin day 6 continue day 17 blood count recover . Treatment continue every 3 week maximum 6 course absence stable progressive disease completion course 2 complete response completion course 4 . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable metastatic urothelial cancer No transitional cell histology Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Hematopoietic : WBC least 3,500/mm^3 Platelet count great 150,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 55 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : No concurrent malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>